Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593637 | 0.81 | KMT2A (0.34) | KMT2ALATS1LATS2 | |
| SCHEMBL21593630 | 0.80 | KMT2A (0.33) | KMT2ALATS1LATS2 | |
| SCHEMBL21593590 | 0.79 | KMT2A (0.33) | KMT2ATYRO3MERTKLATS1LATS2 | |
| SCHEMBL21593660 | 0.79 | KMT2A (0.44) | KMT2AFLT3TYRO3MERTKGAS6 | |
| SCHEMBL20330481 | 0.77 | MAPK8 (0.37) | KMT2AFLT3TYRO3MERTKGAS6 | |
| SCHEMBL20329968 | 0.76 | SYK (0.46) | KMT2A | |
| SCHEMBL30736504 | 0.76 | SYK (0.46) | KMT2A | |
| SCHEMBL21593677 | 0.70 | KMT2A (0.59) | KMT2AFLT3TYRO3MERTKGAS6 | |
| SCHEMBL21593664 | 0.68 | KMT2A (0.43) | AURKAKMT2AFLT3TYRO3MERTK | |
| SCHEMBL17168786 | 0.66 | LATS1 (0.36) | KMT2ALATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |